Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 17

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 17
---
 clinical trials.                                                                                                                                                                                                                                                                                                                                                      |

<div align='center'>S-10</div>

| · | We rely on third parties to conduct our clinical trials and to obtain materials or supplies necessary to conduct trials or to manufacture our product candidates, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates.                                                                                 |
| · | We face potential risks associated with future changes in laws and policies, including the availability of government funding for grants, staffing and funding of regulatory agencies.                                                                                                                                                                                                                  |
| · | The use or anticipated use of artificial intelligence (“AI”) technologies, including generative AI, by us or third parties, may increase or create new operational risks.                                                                                                                                                                                                                               |
| · | Our business operations and current and future relationships with clinical site investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.                                                                                                            |
| · | If you purchase securities in an offering, you may incur dilution.                                                                                                                                                                                                                                                                                                                                      |
| · | We will have broad discretion in the use of the net proceeds from an offering and may not use them effectively.                                                                                                                                                                                                                                                                                         |
| · | Innoviva, Inc. (together with its wholly owned subsidiary, Innoviva Strategic Opportunities LLC, “Innoviva”), our principal shareholder, beneficially owns greater than 50% of our outstanding shares of common stock, which causes us to be deemed a “controlled company” under the rules of the NYSE. In addition, Innoviva’s interests in our business may be different than our other shareholders. |

Corporate Information Our principal executive office is located at 5005 McConnell Avenue, Los Angeles, CA 90066 and our telephone number is (310) 665-2928. Our website is https://www.armatapharma.com. Information contained on, or available through, our website does not constitute part of, and is not deemed incorporated by reference into, this prospectus supplement or the accompanying base prospectus, and investors should not rely on such information in deciding whether to purchase shares of our common stock.

<div align='center'>S-11</div>

THE OFFERING

| Common stock offered by us                                     |     | Shares of our common stock, par value $0.01 per share, having an aggregate                                                                                                                                                                                                                                                                                                                                
 offering price of up to $100,000,000 subject to certain conditions.                                                                                                                                                                                                                                                                                                                                       |
| Common stock to be outstanding immediately